Report : Europe Human Leukocyte Antigen (HLA) Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and service (Reagents & Consumables, Instruments, and Software & Services), Technology (Molecular Assay Technologies and Non-Molecular Assay Technologies), and End User (Independent Reference Laboratories, Hospitals and Transplant Centers, and Others)
At 7.3% CAGR, the Europe Human Leukocyte Antigen (HLA) Testing Market is speculated to be worth US$ 287.77 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Europe human leukocyte antigen (HLA) testing market was valued at US$ 188.49 million in 2022 and is expected to reach US$ 287.77 million by 2028, registering an annual growth rate of 7.3% from 2022 to 2028. Increasing plasma donation and organ transplants procedures and increasing applications of HLA testing for human leukocyte antigen (HLA) testing are the critical factors attributed to the market expansion.
Human leukocyte antigens (HLAs) are the specialized proteins present on all cell surfaces of the human body, except red blood cells. HLA testing has significant application in organ transplantation, which can be recommended as a part of the treatment of kidney failure, chronic liver cirrhosis, and chronic heart disease, among other medical issues. The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing. Before transplantation, HLA testing is performed to check tissue compatibility between patients and donors to avoid graft rejection. In recent years, transplantation has become a successful practice worldwide. Thus, the growing demand for organ transplantation leads to the requirement of a more substantial number of HLA testing kits and consumables, which drives the growth of the HLA testing market.
On the contrary, increasing accuracy errors of Europe human leukocyte antigen (HLA) testing market .
Based on product & services, Based on product market is segmented into reagents & consumables, instruments, and software & services. The Reagents & consumables segment held 52.49% market share in 2022, amassing US$ 98.94 million. It is projected to garner US$ 154.27 million by 2028 to expand at 7.7% CAGR during 2022–2028.
Based on technology, the Europe human leukocyte antigen (HLA) testing market is divided into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies sub segmented into PCR-based molecular assays, sequencing-based molecular assays and others. The molecular assay technologies, segment held 83.31% market share in 2022, amassing US$ 157.02 million. It is projected to garner US$ 242.24 million by 2028 to expand at 7.5% CAGR during 2022–2028.
Based on end user, the Europe human leukocyte antigen (HLA) testing market is divided into independent reference laboratories, hospital and transplant centers, and others. The independent reference laboratories segment held 48.11% market share in 2022, amassing US$ 90.68 million. It is projected to garner US$ 137.18 million by 2028 to expand at 7.1% CAGR during 2022–2028.
Based on country, the Europe human leukocyte antigen (HLA) testing market has been categorised into the U.K., Germany, France, Italy, Spain and Rest of Europe. Our regional analysis states that Germany captured 28.58% market share in 2022. It was assessed at US$ 53.88 million in 2022 and is likely to hit US$ 83.12 million by 2028, exhibiting a CAGR of 7.5% during the forecast period.
Key players dominating the Europe human leukocyte antigen (HLA) testing market are THERMO FISHER SCIENTIFIC INC.; CareDx; QIAGEN; Illumina, Inc.; Bio-Rad Laboratories, Inc.; F. HOFFMANN-LA ROCHE LTD.; Takara Bio Inc.; Luminex Corporation; Omixon Inc.; Protrans; and CeGaT GmbH among others.
- In April 2022, CareDx, Inc. announced the launch of a fully functional next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden to support companies in research and academic studies working on HLA applications in vaccine and drug development as well as disease association studies.
- In August 2022, BioReference Laboratories announced that it has acquired the Ariosa centralized prenatal testing business from Roche. Ariosa’s non-invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, has been performed in over 1.5 million patients. The acquisition of Ariosa will complement current NIPS offering.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: email@example.com